Skip to Main Content

Paper Details

The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.
Nat Genet
7
2024
A3B, A3B deficiency, APOBEC, APOBEC mutation, APOBEC3B, EGFR, EGFRmut, NF-B, NSCLC, apolipoprotein B mRNA-editing catalytic subunit-like, cancer, epidermal growth factor receptor, human, human NSCLC models, lung cancer, lung tumor, mouse, non-small-cell lung cancer, nuclear factor kappa B, patients, tumors
Author NameAffiliation
Collin M BlakelyUniversity of California san francisco
Caroline E McCoach
Victor OlivasUniversity of California san francisco
William L BrownUniversity of Minnesota
Pier SelenicaMemorial Sloan Kettering Cancer Center
Eliezer M Van AllenDana-Farber Cancer Institute
Eliezer M Van AllenDana-Farber Cancer Institute
Reuben S HarrisUniversity of Texas Health San Antonio
Reuben S HarrisHoward Hughes Medical Institute, University of Texas Health San Antonio
Trever G BivonaHelen Diller Family Comprehensive Cancer Center, University of California san francisco
Trever G Bivona
Charles SwantonThe Francis Crick Institute
Charles SwantonCancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute
  • 1 - 13

Datasets

Release 1.2